A method of producing a transgenic silkworm that spins bagworm silks and producing a large quantity of bagworm silks by transgenic technology is developed and provided. A gene encoding a modified bagworm Fib H and a transgenic silkworm in which the gene is introduced, wherein the gene is obtained by cloning a gene fragment encoding a bagworm Fib H-like polypeptide comprising a partial amino acid sequence of bagworm Fib H, and fusing the gene fragment to a gene fragment encoding silkworm-derived Fib H, are provided.

Provided are recombinant Factor VIII proteins, e.g., human Factor VIII proteins with heterologous moieties inserted into flexible permissive loops located in the Factor VIII A domains, while retaining the procoagulant activity of Factor VIII.

The present disclosure provides humanized antibodies, including antibodies comprising an ultralong CDR3 and uses thereof.

There is provided a compound of formula (I), A-Q-B I wherein Q represents a structural fragment of formula (II), wherein: the squiggly lines and m have meanings given in the description, and wherein A and B have meanings given in the description, but may represent a peptide component of the amino acid sequence: [W-Lys-X.sup.1-Ser-U—X.sup.2—Y].sub.n—W-Lys-X.sup.1-Ser-U—X.sup.2—Y— (SEQ ID No: 3) wherein the dashed line, n, W, X.sup.1, U, X.sup.2 and Y have meanings given in the description, which compounds are useful in medicine, including as pharmaceutical excipients, adhesives and film-forming materials and/or are useful in the treatment of conditions characterised by inflammation, including wounds, burns, and disorders of the mucosa, such as anorectal diseases, inflammatory bowel diseases, gynaecological diseases and dental diseases.

##STR00001##

A voltage indicator includes a polypeptide sequence comprising a voltage-sensitive opsin domain and a capture protein domain arranged and disposed to capture a fluorescent dye ligand. When the fluorescent dye ligand is captured and the voltage indicator is bound to a cell membrane, an increase in voltage across the cell membrane causes an increase in fluorescent emission.

A photoelectric device is disclosed. The photoelectric device includes a first electrode, a second electrode, and an electrolyte disposed between the first electrode and the second electrode. The second electrode includes a transparent layer for allowing light to penetrate into the second electrode, an electron transport layer coupled to the transparent layer, and a genetically hybridized fluorescent silk layer as a photo-sensitizer coupled to the electron transport layer.

The present invention relates to an isolated peptide modified based on the histidine-rich beak peptide (HBpep), which is derived from the Humbolt squid beak protein. In a preferred embodiment, the isolated peptide comprises the amino acid sequence of GHGVYGHGVYGHGPYKGHGPYGHGLYW (SEQ ID NO: 10), which contains a single lysine residue inserted at position 16 from the N-terminal of HBpep. In a further preferred embodiment, the lysine residue is conjugated with a self-immolative moiety, preferably comprising a disulfide moiety. The present invention also relates to a composition for the delivery of an active agent, wherein the composition comprises a peptide coace rvate comprising the isolated peptide and the active agent recruited in the peptide coace rvate. The present invention further relates to a method of recruiting the active agent in the peptide coace rvate, a method of delivering the active agent, and a method of treating or diagnosing a condition or disease in a subject.

The present invention provides a polypeptide capable of crossing the blood-brain barrier. In the present invention, C-terminal of the ziconotide is linked to N-terminal of a cell membrane penetrating peptide via one glycine to obtain a polypeptide capable of crossing the blood-brain barrier. The polypeptide of the present invention is suitable for intravenous, intraperitoneal or nasal administration with convenient operation and low clinical risk. It has a long pharmacological effect in vivo, excellent analgesic effect, and slight peptide side effect after intravenous, intraperitoneal or nasal administration, and is suitable for large-scale clinical applications. The polypeptide of the invention has the advantages of simple preparation, controllable preparation process and quality during the preparation, and is suitable for large-scale industrial production.

A coacervate including a catechol-substituted anionic polymer; an adhesive including same; and a method for producing the coacervate are described. More specifically, a coacervate formed by mixing a catechol derivative of a mussel adhesive protein and a catechol-substituted anionic polymer; an adhesive including the coacervate; and a method for producing a coacervate are described. The method includes a step of obtaining a catechol-substituted anionic polymer through catechol substitution of an anionic polymer, and a step of mixing the catechol-substituted anionic polymer and a catechol derivative of a mussel adhesive protein.

A cell culture substrate including a substrate provided with a non-porous surface and a cell culture coating layer that covers at least a portion of the non-porous surface, wherein the cell culture coating layer is implemented such that particles formed of fusion proteins for culturing cells are aggregated to form at least a portion of the surface, the fusion proteins comprising functional peptides bound to mussel adhesive proteins. In particular, despite containing compounds such as proteins that are beneficial to culturing cells, the cell culture substrate can be stored at room temperature for a long period of time over several years, exhibiting excellent storage stability, while activities of such compounds that are beneficial to culturing of the cells remain unchanged or only suffer minimal degradation so that the cells can be cultured at an initially-designed level.